This is one of the few possible neuroprotective trials and they are recruiting right now.
A compound that researchers believe may lower the risk of Parkinson's disease (PD) and slow progression is now in the final stage of clinical testing. The Safety of Urate Elevation in Parkinson's Disease Phase III study (SURE-PD3) is recruiting people diagnosed with Parkinson's within the last three years. SURE-PD3 aims to enroll 270 people across 60 U.S. clinical sites for the two-year study. Forty-five sites are now actively recruiting. It won't be open long!